What breaks when medical devices are left outside normal security controls?

Why This Matters for Security Teams

Medical devices are not ordinary endpoints. Many run embedded operating systems, rely on vendor-managed software cycles, and support clinical availability requirements that make standard patching, EDR, and hardening patterns difficult to apply. When those devices sit outside normal security controls, the gap is usually not just technical. It becomes a governance issue across asset inventory, network segmentation, identity, and incident response.

NIST’s NIST SP 800-53 Rev 5 Security and Privacy Controls is useful here because it frames the need for asset management, access control, monitoring, and system integrity as connected controls rather than isolated tasks. That matters in healthcare, where a device that cannot be fully hardened still needs to be accounted for, restricted, and observed. The practical risk is that clinical uptime often gets treated as a reason to defer security ownership, leaving biomedical engineering, IT, and security each assuming another team is handling it.

In practice, many security teams encounter the real impact only after lateral movement has already started from a device that was never brought into the normal control baseline.

How It Works in Practice

When a medical device is outside normal controls, the failure usually begins with visibility. If the device is not in the asset inventory, it cannot be risk-rated, monitored, or patched on a defined cycle. If it is not placed into a protected network zone, it can communicate too broadly. If its service account, shared credential, or vendor remote access path is not governed, it becomes an identity problem as much as a device problem.

For hospitals and care networks, the most effective response is to treat medical devices as a separate but governed class of assets. That means defining which controls are mandatory, which are compensating, and which are explicitly exempted with approval. The usual control stack includes:

• Asset discovery and ownership assignment so no device is “unknown” for long.
• Network segmentation to separate clinical devices from user workstations and general server zones.
• Restricted administrative access, ideally tied to named identities rather than shared logins.
• Central logging of available events, even if telemetry is limited compared with standard endpoints.
• Vendor access governance, with time-bound approval and review of remote support pathways.

Healthcare guidance from CISA and HHS also stresses that medical devices often need compensating controls when full endpoint tooling is not feasible, which is why monitoring and segmentation become core security measures rather than nice-to-have add-ons. Security teams should also align incident response with patient safety, because disconnecting a device may create operational or clinical risk. The operational question is not whether the device is “secure enough” in the abstract, but whether its exposure is bounded well enough to prevent it becoming a bridge into identity services, imaging systems, backup platforms, or EHR-connected infrastructure. These controls tend to break down when legacy devices share flat networks with general-purpose systems because lateral movement becomes easy and device-level telemetry is too limited to detect abuse early.

Common Variations and Edge Cases

Tighter segmentation often increases operational overhead, requiring organisations to balance clinical availability against containment and monitoring depth.

Not every medical device fails in the same way. Some have stronger logging and patch support, while others are effectively static platforms with long vendor replacement cycles. Best practice is evolving for connected and AI-enabled devices, especially where software updates may change model behavior, data flows, or remote service dependencies. In those environments, security review should include provenance of firmware and update packages, not just network controls.

There is also a real tradeoff around shared clinical equipment, contractor-maintained devices, and temporary deployments. Mobile carts, diagnostic tools, and vendor service laptops often bypass normal onboarding because they are seen as short-lived. That is precisely why they are risky. If a device cannot support full monitoring, it should be placed behind stronger compensating controls and time-limited access. Where identity controls are weak, even a well-segmented device can still be abused through stolen service credentials or overprivileged vendor accounts. If the environment mixes life-critical systems, legacy operating systems, and flat broadcast-heavy networks, the guidance becomes harder to apply consistently because containment can interfere with uptime, interoperability, and clinical workflows.

For organisations mapping these gaps to formal governance, the practical question is whether exceptions are temporary and reviewed, or simply normalised into the environment.

Related resources from NHI Mgmt Group

• What breaks when routers and cameras are left outside normal security governance?
• What breaks when legacy service accounts are left outside modern identity controls?
• What breaks when secrets are left outside the normal identity lifecycle?
• What breaks when AI gateway controls are treated like ordinary API security?